0001104659-21-064322.txt : 20210511 0001104659-21-064322.hdr.sgml : 20210511 20210511092937 ACCESSION NUMBER: 0001104659-21-064322 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210510 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Quanterix Corp CENTRAL INDEX KEY: 0001503274 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 208957988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38319 FILM NUMBER: 21909887 BUSINESS ADDRESS: STREET 1: 900 MIDDLESEX TURNPIKE CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 617-301-9400 MAIL ADDRESS: STREET 1: 900 MIDDLESEX TURNPIKE CITY: BILLERICA STATE: MA ZIP: 01821 8-K 1 tm2115832d1_8k.htm FORM 8-K
0001503274 false 0001503274 2021-05-10 2021-05-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 10, 2021

 

QUANTERIX CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware 001-38319 20-8957988
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer
Identification No.)

 

900 Middlesex Turnpike
Billerica, MA
01821
(Address of principal executive offices) (zip code)

 

Registrant’s telephone number, including area code: (617) 301-9400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

 

Emerging Growth Company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  Trading symbol(s)  Name of each exchange on which registered
Common Stock, $0.001 par value per share  QTRX  The Nasdaq Global Market

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 11, 2021, Quanterix Corporation (the “Company”), issued a press release announcing the appointment of Masoud Toloue as President of Quanterix Corporation and Diagnostics, effective June 9, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Dr. Toloue, age 41, joins the Company from PerkinElmer where he served as Vice President and General Manager, Diagnostics from July 2019 to January 2021 and as Senior Vice President, Diagnostics from February 2021 to the present. From August 2016 to June 2019, he served as Vice President and General Manager of PerkinElmer’s Applied Genomics business. In connection with his employment, Dr. Toloue and the Company have entered into an employment agreement (the “Employment Agreement”) as of May 10, 2021. Under the Employment Agreement, Dr. Toloue’s at-will employment with the Company will commence on June 9, 2021. His initial annualized base salary will be $525,000. Dr. Toloue will be eligible to receive an annual performance bonus with an annual bonus target of up to $525,000. Dr. Toloue’s bonus for 2021 will be determined based his actual base salary earned during the year. Dr. Toloue will also receive a sign-on equity award consisting of 50,703 restricted stock units (the “Sign-On Equity Award”). The Sign-On Equity Award will vest over three years, with one-third vesting on the first anniversary of Dr. Toloue’s actual start date and the remainder vesting ratably on a monthly basis over the next two years. Dr. Toloue will also be eligible to receive a sign-on cash payment of $100,000 payable as soon as practicable after his start date. Dr. Toloue will also be eligible to receive an annual equity grant as part of the Company’s the Company’s next long-term equity award cycle, which is expected to commence in 2022. The Company will target grant date fair value of the annual equity awards of up to $1,600,000.

 

If Dr. Toloue’s employment is terminated by the Company without cause or he resigns for good reason, he will receive continued payment of his base salary for twelve months (the “Severance Period”), payment of an amount equal to his annual target bonus for the year of termination, acceleration of any of the unvested portion of the Sign-On Equity Award that would have vested during the Severance Period had he remained employed during such time, and health benefits continuation during the Severance Period. If Dr. Toloue’s employment is terminated by the Company without cause or he resigns for good reason in connection with a change-in-control, all of his outstanding but unvested equity awards will become fully vested. Receipt of the foregoing termination benefits will be subject to Dr. Toloue’s execution of a separation agreement, including certain restrictive covenants and a general release of all claims, in a form acceptable to the Company.

 

The foregoing description of the principal terms of the Employment Agreement is qualified in its entirety by reference to the Employment Agreement, a copy of which is attached as Exhibit 10.1 and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits

 

  (d) Exhibits

 

Exhibit
No.
   Description
     
10.1   Employment Agreement between Dr. Toloue and the Company dated May 10, 2021.
     
99.1   Press Release dated May 11, 2021.
     
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  QUANTERIX CORPORATION
   
  By: /s/ John Fry
    John Fry
    General Counsel and Secretary
     

Date: May 11, 2021

 

 

 

EX-10.1 2 tm2115832d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

 

 

May 10, 2021

 

Masoud Toloue

 

Re:      Employment Agreement

 

Dear Masoud:

 

Quanterix Corporation (the “Company”) is pleased to offer you the full-time position of President of Quanterix Corporation and Diagnostics, reporting to me. Your start date will be on June 9, 2021. We are excited about the prospect of you joining our team.

 

1.             Base Salary: The Company will pay you a salary at an annual rate of $525,000.00, paid at a bi-weekly rate of $20,192.31, subject to periodic review and adjustment at the discretion of the Company.

 

2.             Bonus: You will be eligible to receive an annual performance bonus beginning with the Company’s 2021 performance year. Your annual bonus target will be up to $525,000.00 (the “Target Bonus”). The actual amount earned will be subject to the achievement of the metrics and goals established by the Company. The annual bonus will be subject to approval by and adjustment at the discretion of the Company, and the terms of any applicable bonus plan or award. Your bonus for 2021 will be determined based on your actual base salary earned during the year.

 

3.             Benefits: You will be eligible to participate in the employee benefits and insurance programs generally made available to its full-time employees, including medical insurance, dental insurance, 401K Plan and match, ESPP, Flexible Spending Account, term life insurance, and short and long term disability insurance. Details of these benefits programs, including mandatory employee contributions, will be made available to you when you start. You also will be eligible to receive paid vacation time. You will be eligible for up to 20 days of paid vacation per year, which shall accrue on a prorated basis. Other provisions of the Company’s vacation policy are set forth in the policy itself.

 

4.             Sign-On Equity Award: You will be eligible to receive a sign-on equity award consisting of 50,703 restricted stock units (RSUs). Your sign-on equity award will vest over a three-year period, with one-third vesting on the first anniversary of your actual start date. The remainder will vest ratably on a monthly basis over the next two years. Your award will also be subject to the terms of our 2017 Employee, Director and Consultant Equity Incentive Plan and the Company’s form of award agreements. 

 

 

 

 

Masoud Toloue

Employment Agreement

Page 2 

 

5.             Long Term Equity Incentive Award: You will also be eligible to receive an annual equity grant as part of the Company’s next long term equity incentive award cycle, which we expect to commence in the first quarter of 2022. The Company will target a grant date fair value of the annual equity awards of up to $1,600,000.00. The value of your award will be discretionary and will be subject to your achievement of the metrics and goals established by the Company. Your equity grant will be subject to valuation methodologies and other terms and conditions applicable to other similarly situated executives of the Company, and will be subject to Compensation Committee approval.

 

6.             Sign-On Cash Payment: As further inducement to joining our Company and in consideration of amounts forfeited by leaving your present position, you will be eligible to receive a sign-on cash payment in the amount of $100,000.00, payable as soon as practicable after your actual start date. You will be required to repay 50% of your sign-on cash payment should you voluntarily terminate your employment with the Company without Good Reason (as defined below) within one year of your start date.

 

7.             At-Will Employment; Accrued Obligations: Your employment is “at will,” meaning you or the Company may terminate your employment at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall pay you the “Accrued Obligations,” defined as (1) your base salary through the date of termination; (2) an amount equal to the value of your accrued unused vacation days; (3) the amount of any expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed; and (4) to the extent not theretofore paid or provided, any other amounts or benefits required to be paid or provided or which you have earned under any plan or agreement of or with the Company through the date of termination.

 

 

 

 

Masoud Toloue

Employment Agreement

Page 3 

 

8.             Severance: Without limiting the at-will nature of your employment relationship, if the Company terminates your employment without Cause, or if you resign for Good Reason, the Company shall provide you with the following termination benefits (the “Termination Benefits”):

 

(a)Salary Continuation Payments. Continuation of your base salary for a period of twelve (12) months after the date of termination (the “Severance Period”) at the salary rate then in effect.

 

(b)Target Bonus. An amount equal to your applicable annual target bonus for the year of termination, paid in one lump sum on the Company’s next regularly-scheduled payroll date following the effective date of the separation agreement described below.

 

(c)Acceleration of Sign-On Equity Award. Notwithstanding anything to the contrary in the applicable equity plan or the award agreement applicable to your Sign-On Equity Award, any outstanding but unvested portion of your Sign-On Equity Award that would have vested during the Severance Period had you remained employed during such time shall accelerate and become fully-vested and exercisable as of the later of (A) the termination date, or (B) the effective date of the separation agreement described below.

 

(d)Health Benefits Continuation. Continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of (i) the end of the Severance Period; or (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA (“Health Benefits Continuation Payments”). Notwithstanding the above, (x) in the event that the Severance Period extends beyond eighteen (18) months following your date of termination, or (y) if the Company otherwise determines in its sole discretion that it cannot provide the foregoing Health Benefits Continuation Payments without potentially violating applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the Company’s portion of the monthly COBRA premium (as described above) that you would be required to pay to continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether COBRA continuation coverage remains available (i.e., in the event that the Severance Period extends beyond eighteen (18) months following your date of termination) and shall end on the earlier of (1) the end of the Severance Period, (2) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA; or (3) the last day of the twenty-fourth (24th) calendar month following your termination date.

 

 

 

 

Masoud Toloue

Employment Agreement

Page 4

 

If the Company terminates your employment without Cause, or if you resign for Good Reason, and the effective date of such termination occurs within the 90 day period immediately preceding or the twelve (12) month period immediately following a Change-in-Control (such period the “Change-in-Control Period” and such termination a “Change-in-Control Termination”), then in addition to the Termination Benefits set forth immediately above:

 

Equity Acceleration. Notwithstanding anything to the contrary in any applicable equity plan or award agreement, all of your outstanding but unvested equity awards shall accelerate and become fully-vested and exercisable as of the later of (A) the termination date, or (B) the effective date of the separation agreement described below, or (C) as of the Change-in-Control.

 

Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination Benefits unless (a) within 60 days of your date of termination, you first (i) enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company, which shall include a general release in favor of the Company and related persons and entities, and other provisions regarding non-competition, confidentiality, cooperation, non-disparagement and the like as may be included in the Company’s then current form of separation agreement (the “Release”); (ii) resign from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii) return all Company property and comply with any instructions related to deleting and purging duplicates of such Company property, and (b) you comply with the terms of your Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement or any other similar agreements with the Company. The Salary Continuation Payments shall commence within 60 days after the date of termination and shall be made on the Company’s regular payroll dates; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid in the second calendar year. In the event you miss a regular payroll period between the date of termination and the first Salary Continuation Payment, the first Salary Continuation Payment shall include a “catch up” payment.

 

For purposes of this Section:

 

Cause” means the occurrence of any of the following (and, if applicable, that the Company has complied with the Cause Process (hereinafter defined) following the occurrence of a circumstance subject to the Cause Process): (i) theft, fraud, embezzlement, misappropriation of assets or property of the Company, or material violation of your Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement; (ii) dishonesty, gross negligence, misconduct, neglect of duties, or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) breach of an employment, consulting or other agreement with the Company; (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendere; or (vi) continued, willful and deliberate non-performance by you of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability).

 

 

 

 

Masoud Toloue

Employment Agreement

Page 5

 

Cause Process” means that (1) the Company has reasonably determined in good faith that a “Cause” condition has occurred; (2) the Company has notified you in writing of the first occurrence of the Cause condition within 60 days of the first occurrence of such condition; (3) you are provided a period of 30 days following such notice (the “Cause Cure Period”) to remedy the condition; (4) notwithstanding such efforts, the Company reasonably and in good faith determines at the end of the Cause Cure Period that the Cause condition continues to exist; and (5) the Company terminates your employment within 30 days after the end of the Cause Cure Period. If you cure the Cause condition during the Cause Cure Period, Cause shall be deemed not to have occurred. The Company shall not be required to follow the Cause Process as to those conditions which it reasonably determines in good faith cannot be cured within the Cause Cure Period. For the avoidance of doubt, you and the Company acknowledge and agree that clauses (i), (iii) and (v) cannot be cured, and shall not be subject to the requirements of the Cause Process.

 

Change-in-Control” means the occurrence of any of the following events: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; (ii) a change in the composition of the Company’s Board of Directors occurring within a two-year period, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” will mean directors who either (A) are directors of the Company as of the date hereof, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company); (iii) the consummation of a merger or consolidation of the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (iv) the consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets.

 

 

 

 

Masoud Toloue

Employment Agreement

Page 6

 

Good Reason” means that you have complied with the Good Reason Process following the occurrence of any of the following actions undertaken by the Company without your express prior written consent: (i) the material diminution in your authority, duties and responsibilities; (ii) a material reduction in your base salary, provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your base salary that is pursuant to a salary reduction program affecting or a material portion of the similarly situated senior level employees of the Company and that does not adversely affect you to a greater extent than such similarly situated employees; and (iii) a change in the geographic location at which you must regularly report to work and perform services of more than thirty (30) miles, except for required travel on the Company’s business; or (v) a material breach by the Company of any of its obligations to you under its employment agreements with you.

 

Good Reason Process” means that (1) you have reasonably determined in good faith that a “Good Reason” condition has occurred; (2) you have notified the Company in writing of the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (3) the Company is provided with a period of 30 days following such notice (the “Cure Period”) to remedy the condition; (4) notwithstanding such efforts, you reasonably and in good faith determine at the end of the Cure Period that the Good Reason condition continues to exist; and (5) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

 

9.             Section 280G:

 

(a)If any payment or benefit you would receive under this Agreement, when combined with any other payment or benefit you receive pursuant to a Change-in-Control (for purposes of this Section, a “Payment”) would constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and, but for this sentence, be subject to the excise tax imposed by Code Section 4999 (the “Excise Tax”), then such Payment shall be either: (i) the full amount of such Payment; or (ii) such lesser amount (a “Reduced Payment”) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employment taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.

 

(b) With respect to Section 10(a), if there is more than one method of reducing the Reduced Payment amount that would result in no portion of the Payment being subject to the Excise Tax, then the Payment shall be reduced or eliminated in the following order: (i) cash payments; (ii) taxable benefits; (iii) nontaxable benefits; and (iv) accelerated vesting of equity awards in a manner that maximizes the amount to be received by you.

 

 

 

 

Masoud Toloue

Employment Agreement

Page 7

 

(c)The determination of whether Section 10(a)(i) or (ii) applies, and the calculation of the amount of the Reduced Payment if applicable, shall be performed by a nationally recognized certified public accounting firm as may be designated by the Company (the “Accounting Firm”). The Accounting Firm shall provide detailed supporting calculations to both the Company and you within fifteen (15) business days of the receipt of notice from you that there has been a Payment, or such earlier time as is requested by the Company, in a form that can be relied upon for tax filing purposes. All fees and expenses of the Accounting Firm shall be borne solely by the Company.

 

(d)You may receive a Payment that is, in the aggregate, either more or less than the amount described in Section 10(a)(i) or (ii) (as applicable, an “Overpayment” or “Underpayment”). If it is finally determined by a court of competent jurisdiction pursuant to a final non-appealable judgment, or the Internal Revenue Service, or by the Accounting Firm upon request by either the Company or you, that an Overpayment or Underpayment has been made, then: (i) in the event of an Overpayment, you shall promptly repay the Overpayment to the Company, together with interest on the Overpayment at the applicable federal rate from the date of your receipt of such Overpayment until the date of such repayment; and (ii) in the event of an Underpayment, the Company shall promptly pay an amount equal to the Underpayment to you, together with interest on such amount at the applicable federal rate from the date such amount would have been paid to you had the provisions of Section 10(a)(ii) not been applied until the date of payment.

 

10.           Section 409A: Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your “separation from service.” The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate “payment” for purposes of Section 409A. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 

 

 

 

Masoud Toloue

Employment Agreement

Page 8

 

11.           No Guarantee of Tax Consequences: The Company makes no guarantee of any tax consequences with respect to any payment hereunder, including, without limitation, under Section 409A of the Code.

 

12.          No Mitigation: In no event, except as set forth expressly in this or another agreement signed by you, shall you be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to you under any of the provisions of this Agreement and, subject to the aforesaid exception, such amounts shall not be reduced whether or not you obtain other employment.

 

13.          Return of Company Property: Upon termination of employment for any reason, you shall promptly return to the Company any keys, credit cards, passes, confidential documents or material, computer equipment, or other property belonging to the Company, and you shall also return all writings, files, records, correspondence, notebooks, notes and other documents and things (including any copies thereof) containing confidential information or relating to the business or proposed business of the Company or its affiliated entities or containing any trade secrets relating to the Company or its affiliated entities. For purposes of the preceding sentence, the term “trade secrets” shall have the meaning ascribed to it under the Uniform Trade Secrets Act. You agree to represent in writing to the Company upon termination of employment that you have complied with the foregoing provisions of this Section.

 

14.          Assistance with Claims: You agree that, consistent with your business and personal affairs, during and after your employment by the Company, you will assist the Company and its affiliated entities in the defense of any claims, or potential claims that may be made or are threatened to be made against any of them in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), and will assist the Company and its affiliated entities in the prosecution of any claims that may be made by the Company or its affiliated entities in any Proceeding, to the extent that such claims may relate to your employment or the period of your employment by the Company. The Company agrees to reimburse you for your reasonable out-of-pocket expenses associated with such assistance, including travel expenses. Any amounts to be paid to you pursuant to this Section 15 shall be paid by the Company within no later than thirty (30) days of the date on which you provide documentation to the Company that such expenses were incurred.

 

 

 

 

Masoud Toloue

Employment Agreement

Page 9

 

15.           Representation Regarding Other Obligations: This offer is conditioned on your representation that you are not subject to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company. If you have entered into any agreement that may restrict your activities on behalf of the Company, please provide me with a copy of the agreement as soon as possible.

 

16.          Restrictive Covenants: You will be required to sign the Company’s standard “Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement” as a condition of your employment. A copy of that Agreement is enclosed. If the Company elects to enforce a non-competition provision for which post-employment payments are required under applicable law (“Non-Competition Payment”), the Company may apply the amount of any Non-Competition Payment to the Termination Benefits.

 

17.          Other Terms: Your employment with the Company shall be on an at-will basis. In other words, you or the Company may terminate employment for any reason and at any time, with or without notice. In addition, as with all employees, our offer to you is contingent on your submission of satisfactory proof of your identity and your legal authorization to work in the United States.

 

We are excited about the opportunity to work with you at Quanterix. If you have any questions about this information, please do not hesitate to call. Otherwise, please confirm your acceptance of this offer of employment by signing below and returning a copy to me no later than May 6, 2021.

 

We are confident that with your background and skills, you will have an immediate positive impact on our organization.

 

[Signature Page Follows]

 

 

 

 

Masoud Toloue

Employment Agreement

Page 10

 

Sincerely,  
   
/s/ Kevin Hrusovsky  
Kevin Hrusovsky  
CEO and Executive Chairman  
   
AGREED TO AND ACCEPTED  
   
/s/ Masoud Toloue  
Masoud Toloue  

 

 

 

EX-99.1 3 tm2115832d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

tm21158321d1_ex99-1img001 

 

Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnostics

 

Toloue brings deep expertise and industry acumen to lead the Company’s strategic expansion into diagnostics

 

Billerica, Mass. – May 11, 2021 Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021.

 

“We are excited to welcome Masoud to our team at such an important moment for Quanterix,” said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. “We are making important strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizations and advances in our neurology suite of assays for Multiple Sclerosis, Alzheimer’s and Parkinson’s research as well as phase III drug trials. Masoud’s strong growth track record of doubling PerkinElmer’s diagnostics franchise, wealth of experience, deep roots in the life sciences and business acumen will be instrumental as we continue implementing our value creation strategy of entering phase III drug trials with leading protein biomarkers, such as Neurofilament Light (Nf-L), Phosphorylated Tau, Amyloid Beta 40 / 42, GFAP and others, that we believe will ultimately have productive diagnostic and health screen utility in the fields of infectious disease, neurology and immunology.”

 

Toloue brings a wealth of industry experience and high growth track record to Quanterix. He joins Quanterix from PerkinElmer, where he most recently served as senior vice president, diagnostics. He previously led that company’s applied genomics business. Prior to this role, he founded and led Bioo Scientific’s next generation sequencing business which was acquired by PerkinElmer in 2016. He also co-founded and led Genohub, where he transformed that company from a supplier of next generation sequencing matching technology to a leading platform provider for manging sequencing projects globally. He holds a doctoral degree in molecular cell biology from the University at Buffalo and was a postdoctoral fellow in biochemistry at The University of Texas Health Science Center at San Antonio.

 

In his new role, Toloue will oversee Quanterix’ growing diagnostics (Dx) business and assume responsibility for the Company’s Accelerator Lab Services, strategic partnerships and corporate development.

 

“Quanterix is empowering a truly innovative approach to highly-sensitive diagnostics that has incredible potential to change the way healthcare in administered,” said Toloue. “I am eager to roll up my sleeves and join this exceptional leadership team to support the company’s continued diagnostics expansion.”

 

To learn more about Quanterix, visit www.quanterix.com/about.

 

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

 

 

 

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Media Contact:

PAN Communications

Staci Didner, (407) 734-7325

quanterix@pancomm.com 

 

 

 

GRAPHIC 4 tm2115832d1_ex10-1img01.jpg GRAPHIC begin 644 tm2115832d1_ex10-1img01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BH;J1HK M69T.&5"0?PKG/[9O?^>O_CJ_X5RXC%PH-*5QI7.IHKEO[9OO^>O_ (ZO^%'] MLWW_ #U_\=7_ KG_M2CV?\ 7S'RLZFBN6_MF^_YZ_\ CJ_X4?VS??\ /7_Q MU?\ "C^U*/9_U\PY6=317+?VS??\]?\ QU?\*/[9OO\ GK_XZO\ A1_:E'L_ MZ^8O\ XZO^%']LWW_/7_QU?\*/[4H]G_7S#E9U-%O_CJ_X4?VI1[/^OF'*SJ:*Y;^V;[_ )Z_^.K_ (4? MVS??\]?_ !U?\*/[4H]G_7S#E9U-%O_CJ_X4?VS??\]?\ QU?\*/[4H]G_ %\PY6=3 M15>QE>:RBDA&7,DT2%%%%4!7O_ /CPN/\ KFW\JX^NPO\ _CPN M/^N;?RKCZ\/-?CCZ%Q"BBBO**"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@#K=,_Y!L'^X*MU4TS_ )!L'^X*MU];1_AQ]$9!1116@%>__P"/"X_ZYM_* MN/KL+_\ X\+C_KFW\JX^O"S7^)'T+B%%%%>64%%%% !1110 4444 %%%% !1 M110 4444 %%%% '6Z9_R#8/]P5;JIIG_ "#8/]P5;KZVC_#CZ(R"BBBM *]_ M_P >%Q_US;^5%FO\2/H7$****\LH**** "BBB@ MHHHH **** "BBB@ HHHH **** .MTS_D&P?[@JW533/^0;!_N"K=?6T?X%Q_US;^5_\ ^/"X_P"N;?RKCZ["_P#^/"X_ MZYM_*N/KPLU_B1]"XA1117EE!1110 4444 %%%% !1110 4444 %%%% !111 M0!UNF?\ (-@_W!5NJFF?\@V#_<%6Z^MH_P ./HC(****T KW_P#QX7'_ %S; M^5%FO\ $CZ%Q"F2310C,LB(/]I@*BO[M;&QFNG& MY8D+8]:X[1]$;Q&)-3U*>1E=R$0'_.!7%2HJ47.;LD4=NCK(NY&#*>A!R*=7 M#""7PGX@ME6=WLKDD;2>W3GW&1S75Q:K!+K$VF*LGG1('+$#;@@'CG/>G4P[ MCK'5-7 O45GG6+<:S_9A63S@F_=@;<8SZUG/XNM-TAM[2[N(HOORQI\H_,U$ M:%26R Z&BL:;Q+8P:9!?D2M#,VP;5&0>5Q'+NH?P=IJGH;QA_.M;QI!%#::>(T50DI M48 &!@5M?\(Y8?88K/;)Y,4GFH-_.[ZU9U+2K755C6Z5B(VW+M;'-#Q4.=-; M7?XC1@H0/B$^3_RP_P#9165HRZ@^N:BEI+;QW!<[A.6!(W'IC_/2NKO_ [I M^HW0N9D<38 W(Y&0*;J/AO3]2F$\B/'+C!>)MI/UI1Q-/9]5;;L(YN6QN(&U MBXFN[.21[=A+%"[9!X(X(K4TRQ@M_!K3)&GFR6SNS[1GD'C-:-OX M.(D3*5=V.7(^O:KL=A!'IWV!0WD",Q@9YQ]:FKB5)63ZK\AG*V$MM'\/I/M1 M&QMZJ.,ELG&/QJOX':&._N8Y05N6C!3_]/PKHF\,::UO!;LLIAA)9$,G M&2^@O=A2>$85HSMX]#ZTY8FFXSCK[UW_D(OT445YXSK=,_P"0 M;!_N"K=5-,_Y!L'^X*MU];1_AQ]$9!1116@$%ZI:RG51DE" !]*Y7[%=?\\) M/RKL:,5QXG!QKM-NPT[''?8KK_GWD_[YH^Q77_/O)_WS747]PUG8SW$=O)_E,<# M&><^G'-5KCQ3_ +YH^Q77_/O)_P!\UHR>)8TB0BW?=YB"7IMB5IC'DGN?E;H#TJN?%T9N MK8+:NMK<>45ED(!V.LS;L#/&(A[\T?V5#^9AS%;[%=?\^\G_ 'S1]BNO^?>3 M_OFM:/Q+9R) _ES(DTGEAG"A0<*>3G'.X8 ))Y&,@U$GB[3&M4N<3B&1E2-S M'D.6!*@8/4X/7&.^,BC^RH?S,.8SOL5U_P ^\G_?-'V*Z_Y]Y/\ OFMC4]7F MTVY4/:QM;&-Y6D\XAE5 "WR[2">>.?RHN_$5E9R7"2).QMUD>4HF0JHJLQZ^ MCJ/J:/[*A_,PYC'^Q77_ #[R?]\T?8KK_GWD_P"^:TW\4V2.T;07*NB/)("B M_(B[?1U/&3[4U?$]LMTL-PABW+(1SD_([AL_0(3_+-']E0_F83_OFC[%=?\ /O)_WS78X'I1@>E']E0_F8Q(44450!1110!3U6:"VTF\GN8S)!' [R(.K* 21^585K+X M=O\ 3C%-9K' LI8+*0^YO+WD[E)S\FV M:Y[R?#?V)@9YE4%G8L9%? B.>",X\LG\QWQ0!+#J6@QZI<7JP+',GF+).$.2 M5\M<8'))WH!@9/Y4Z+5M"G2:22 )&2Q9FB.6S+MZ8SDN.G7.*>FF:'++(ZS& M-S<,N?-*$R@QYQGJ08D/'I]:F2QT:.79YP9HR9F9IB<$2!R6/0?-@_\ UJ ( M_,\.75[9HJI)/(!+!B-\&;#<]?>G:?I>CRR7$46F" VEPJX;IN5= MRE<$\8?@<=<8J"VTBP7Q#;W5GJ$!$4*@6XP[[=I (;/ ^;/3\>:U/M6G6.HW M$#3K'E.BUFPF>S2.Y4M>(7@&""X SZ<<9Z^E/O=3 MM=/V_:9&4L&8!8V?"KU8[0< 9&2>.: )+BQMKM=MQ"L@V-'AN?E888?B*KKH M>F)%+$+./9*K+(#D[@V-V?7.U<_2F2:]IT*R,\Y_=R&-@(W)#!=QX Y&WG/3 M%+/K=C:NZSRNFU#)DPO@J,9(.,-C<,XS0!'/XO:NEI"<4 M:ZW@R2.5V,H(G&?7W/%2:GX*X%Y.9H?*$9XP%0YQCWR^?][VK0U/2GOG62*Y, M#^3) QV;LH^W./0_*,']*TLT9H Y^_\ "L-[%+&)]J/()-C)N48B\OU';GZU M/-HNBU4W*Z7=-9MMN1"QC.W M=\V#CCO7,PW^O6A@MV$DJB'#N]E(V',18-N#$D;L*1QSD4 2ZK8ZS>+"T*.W ME[]D4S*%#_)L)VM]T#>,\L,U+[*P [9S M1<7^L3Z:C&!X)6<>;&D;[HUWX(# '/&.0,GDCBDCEOW@,TBWZH+-F\I,EBZO M@;21G+#UYP: ':O8:A?7D4]E!+;3B*13*T@ YC8*.&/1BIZ=LYXJ.+2+Q?*D MA@GMXX[V.1+=KDDJFT;\_,0PZ3;01RWAER6.W!7&1R0.I]Q#=W.NG4+H20WL-F M9( #$BN5BW.&*[-HQ MV&,>]=%7/Z2=1-[9O<27+126\^Y9%P!B1!&3P"&*DDY]_2N@H **** "BBB@ M HHHH **** "BBB@ HHHH ,4FT&H+Z[2PLIKN0,8X4,CA!DX R<"LP>*],99 M761VCA.)'"?*O.!GZXX]: -K:*-HK"/B_2EA\YI)%A_OF,XZ(3^0<9],-Z&K M%QX@M;>!9O+FD1HI)LQJ#B-"-S*+.?R3'%.RR[,,$&%+EE4'GN5(XH VL4;16!!XNL95A M#QS1R/ D[(0#L# EXJ@FA:9';O;I9Q"%Q&&0#A@GW,_ M3 K1HH H'1=.:%(6M(C&A=E7;P"^0_Y[FS]:@N/#FF7-I]F,!1!&8E\MRI52 MH7 YZ85>.G K6HH S#H&FF5I#;_.23N#L"I+!B5Y^7+*#QCD5)!HNG6R!(;5 M$4%6 &>"I+#\BQ/XU?HH S8] TV+&RWVXC\K =L%!G"GGD#)P#T[5(^C:>X4 M/:QL%01@,,@* P _)F_.KU% &>=%L"P8VXW!67.X\JQR5//(SV/%-&@Z9Y3Q MM:JZN"K;V+%@0!@DG.,*!^%:5% $<,,<"LL:A0S%SCN2 GRAPHIC 5 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 6 qtrx-20210510.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 qtrx-20210510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 qtrx-20210510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 tm2115832d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001503274 2021-05-10 2021-05-10 iso4217:USD shares iso4217:USD shares 0001503274 false 8-K 2021-05-10 QUANTERIX CORPORATION DE 001-38319 20-8957988 900 Middlesex Turnpike Billerica MA 01821 617 301-9400 false false false false true false Common Stock, $0.001 par value per share QTRX NASDAQ XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
May 10, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 10, 2021
Entity File Number 001-38319
Entity Registrant Name QUANTERIX CORPORATION
Entity Central Index Key 0001503274
Entity Tax Identification Number 20-8957988
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 900 Middlesex Turnpike
Entity Address, City or Town Billerica
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01821
City Area Code 617
Local Phone Number 301-9400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol QTRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://quanterix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2115832d1_8k.htm qtrx-20210510.xsd qtrx-20210510_lab.xml qtrx-20210510_pre.xml tm2115832d1_ex10-1.htm tm2115832d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2115832d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2115832d1_8k.htm" ] }, "labelLink": { "local": [ "qtrx-20210510_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "qtrx-20210510_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "qtrx-20210510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "qtrx", "nsuri": "http://quanterix.com/20210510", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115832d1_8k.htm", "contextRef": "From2021-05-10to2021-05-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://quanterix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115832d1_8k.htm", "contextRef": "From2021-05-10to2021-05-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://quanterix.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001104659-21-064322-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-064322-xbrl.zip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end